MT-401-OTS

Phase 1Small molecule

MMarker Therapeutics, Inc.

MT-401-OTS is one of 4 small molecule programs targeting Relapsed AML. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed AMLRecruiting

Relapsed AMLPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Relapsed AML

#DrugCompanyPhaseTrials

Ayvakit

BBlueprint Medicines

Phase 2

1 2

Liposome-Encapsulated Daunorubicin-Cytarabine

MM.D. Anderson Cancer Center

Phase 2

1 3

Enasidenib Mesylate

CChildren's Oncology Group

Phase 2

1 4

MT-401-OTS

MMarker Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Relapsed AML

NCT06552416

Clinical

Trials by Indication[1]

Relapsed AML1 trial

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

Recruiting·MMarker Therapeutics, Inc.·Phase 1·NCT06552416·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MT-401-OTS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MT-401-OTS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MT-401-OTS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Marker Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMarker Therapeutics, Inc.

MT-401-OTS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Relapsed AML1 trial

References

Drug Info

Quick Facts

Related News